Day One Biopharmaceuticals Approves Key Proposals at Annual Meeting

Day One Biopharmaceuticals ( (DAWN) ) just unveiled an announcement.

On June 2, 2025, Day One Biopharmaceuticals held its Annual Meeting of Stockholders where key proposals were approved. These included the election of Natalie Holles and Garry Nicholson as Class I Directors for a three-year term, the ratification of PricewaterhouseCoopers LLP as the independent accounting firm for 2025, and the approval of executive compensation on a non-binding advisory basis. These decisions are crucial for the company’s governance and operational continuity, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (DAWN) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.

Spark’s Take on DAWN Stock

According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.

Day One Biopharmaceuticals shows strong growth potential, particularly with the success of OJEMDA and a solid cash position. However, consistent net losses, negative technical indicators, and a challenging valuation due to ongoing losses present significant risks. The strong momentum from recent earnings highlights provides some optimism, balancing out the weaker financial and technical aspects.

To see Spark’s full report on DAWN stock, click here.

More about Day One Biopharmaceuticals

Day One Biopharmaceuticals operates in the biopharmaceutical industry, focusing on developing and delivering targeted therapies for patients of all ages with cancer. The company is committed to advancing innovative treatments that address significant unmet medical needs.

Average Trading Volume: 1,331,803

Technical Sentiment Signal: Sell

Current Market Cap: $710.6M

For detailed information about DAWN stock, go to TipRanks’ Stock Analysis page.